Literature DB >> 19173375

Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data.

Sebastian Schneeweiss1, Soko Setoguchi, M Alan Brookhart, Liljana Kaci, Philip S Wang.   

Abstract

BACKGROUND: Nonrandomised studies on the causal effects of psychotropic medications may be biased by patient characteristics that are not fully adjusted.
OBJECTIVE: Studies using linked claims databases found that typical antipsychotic medications were associated with increased short-term mortality compared with atypical antipsychotics. It has been suggested that such results may be due to residual confounding by factors that cannot be measured in claims databases. Using detailed survey data we identified the direction and magnitude of such residual confounding.
DESIGN: Cross-sectional survey data. PARTICIPANTS: 17 776 participants aged > or =65 years from the Medicare Current Beneficiary Survey (MCBS). MEASUREMENTS: To determine the association between typical antipsychotic use and potential confounding factors we assessed five factors not measured in Medicare claims data but in the MCBS, i.e. body mass index, smoking, activities of daily living (ADL) score, cognitive impairment and Rosow-Breslau physical impairment scale. We estimated adjusted associations between these factors and antipsychotic use. Combined with literature estimates of the independent effect of confounders on death, we computed the extent of residual confounding caused by a failure to adjust for these factors.
RESULTS: Comparing typical antipsychotic users with atypical antipsychotic users, we found that not adjusting for impairments in the ADL score led to an underestimation of the association with death (-13%), as did a failure to adjust for cognitive impairment (-7%). The combination of all five unmeasured confounders resulted in a net confounding of -5% (range -19% to +2%). After correction, the reported association between typical antipsychotic use and death compared with atypical antipsychotic use was slightly increased from a relative risk (RR) of 1.37 to 1.44 (95% CI 1.33, 1.56). Comparing any antipsychotic use with non-users would result in overestimations of >50% if cognitive impairment remained unadjusted.
CONCLUSION: Claims data studies tend to underestimate the association of typical antipsychotics with death compared with atypical antipsychotics because of residual confounding by measures of frailty. Studies comparing antipsychotic use with non-users may substantially overestimate harmful effects of antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19173375      PMCID: PMC3067056          DOI: 10.2165/00023210-200923020-00006

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  32 in total

1.  STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION.

Authors:  S KATZ; A B FORD; R W MOSKOWITZ; B A JACKSON; M W JAFFE
Journal:  JAMA       Date:  1963-09-21       Impact factor: 56.272

2.  Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.

Authors:  Priscilla Velentgas; William West; Carolyn C Cannuscio; Douglas J Watson; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-09       Impact factor: 2.890

3.  FDA warns antipsychotic drugs may be risky for elderly.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2005-05-25       Impact factor: 56.272

Review 4.  Psychotropic medication use for behavioral symptoms of dementia.

Authors:  Philip S Wang; M Alan Brookhart; Soko Setoguchi; Amanda R Patrick; Sebastian Schneeweiss
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

5.  Confounding by indication.

Authors:  A M Walker
Journal:  Epidemiology       Date:  1996-07       Impact factor: 4.822

6.  Prescription drug coverage, utilization, and spending among Medicare beneficiaries.

Authors:  M Davis; J Poisal; G Chulis; C Zarabozo; B Cooper
Journal:  Health Aff (Millwood)       Date:  1999 Jan-Feb       Impact factor: 6.301

7.  Morbidity and disability in older persons in the years prior to death.

Authors:  J M Guralnik; A Z LaCroix; L G Branch; S V Kasl; R B Wallace
Journal:  Am J Public Health       Date:  1991-04       Impact factor: 9.308

8.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

Authors:  Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

9.  Medicare beneficiaries rate their medical care: new data from the MCBS (Medicare Current Beneficiary Survey).

Authors:  G S Adler
Journal:  Health Care Financ Rev       Date:  1995

10.  A profile of the Medicare Current Beneficiary Survey.

Authors:  G S Adler
Journal:  Health Care Financ Rev       Date:  1994
View more
  10 in total

1.  Comparison of different approaches to confounding adjustment in a study on the association of antipsychotic medication with mortality in older nursing home patients.

Authors:  Krista F Huybrechts; M Alan Brookhart; Kenneth J Rothman; Rebecca A Silliman; Tobias Gerhard; Stephen Crystal; Sebastian Schneeweiss
Journal:  Am J Epidemiol       Date:  2011-09-20       Impact factor: 4.897

2.  Predictors of relapse in Chinese schizophrenia patients: a prospective, multi-center study.

Authors:  Yu-Tao Xiang; Chuan-Yue Wang; Yong-Zhen Weng; Qi-Jing Bo; Helen F K Chiu; Sandra S M Chan; Edwin H M Lee; Gabor S Ungvari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-11-03       Impact factor: 4.328

3.  The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs.

Authors:  John W Jackson; Tyler J VanderWeele; Anand Viswanathan; Deborah Blacker; Sebastian Schneeweiss
Journal:  Am J Epidemiol       Date:  2014-09-18       Impact factor: 4.897

4.  Risk of mortality among individual antipsychotics in patients with dementia.

Authors:  Helen C Kales; Hyungjin Myra Kim; Kara Zivin; Marcia Valenstein; Lisa S Seyfried; Claire Chiang; Francesca Cunningham; Lon S Schneider; Frederic C Blow
Journal:  Am J Psychiatry       Date:  2011-10-31       Impact factor: 18.112

Review 5.  Use and Interpretation of Propensity Scores in Aging Research: A Guide for Clinical Researchers.

Authors:  Dae Hyun Kim; Carl F Pieper; Ali Ahmed; Cathleen S Colón-Emeric
Journal:  J Am Geriatr Soc       Date:  2016-08-22       Impact factor: 5.562

Review 6.  Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations.

Authors:  Dae Hyun Kim; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-06-24       Impact factor: 2.890

7.  Examining the Association Between Comorbidity Indexes and Functional Status in Hospitalized Medicare Fee-for-Service Beneficiaries.

Authors:  Amit Kumar; James E Graham; Linda Resnik; Amol M Karmarkar; Anne Deutsch; Alai Tan; Soham Al Snih; Kenneth J Ottenbacher
Journal:  Phys Ther       Date:  2015-11-12

8.  Field methods in medical record abstraction: assessing the properties of comparative effectiveness estimates.

Authors:  Elizabeth A Cook; Kathleen M Schneider; Jennifer Robinson; June Wilwert; Elizabeth Chrischilles; Jane Pendergast; John Brooks
Journal:  BMC Health Serv Res       Date:  2014-09-15       Impact factor: 2.655

9.  Factors associated with post-acute functional status and discharge dispositions in individuals with spinal cord injury.

Authors:  Shivayogi V Hiremath; Amol M Karmarkar; Amit Kumar; Donna L Coffman; Ralph J Marino
Journal:  J Spinal Cord Med       Date:  2021-02-19       Impact factor: 1.985

Review 10.  Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis.

Authors:  John W Jackson; Sebastian Schneeweiss; Tyler J VanderWeele; Deborah Blacker
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.